BIVI - Why Is Alzheimer's-Focused BioVie Stock Trading Lower Today? | Benzinga
BioVie Inc (NASDAQ: BIVI) shares are trading lower after the company released an analysis of unblinded, topline efficacy data from its Phase 3 trial of NE3107 for mild to moderate Alzheimer's Disease.
The trial, initiated during the COVID-19 pandemic, enrolled 439 patients. However, the company found significant deviation from protocol violations, which led to the exclusion of all patients from 15 ...